Insights › Market reaction

How Pfizer Stock Reacted to Its Q2 2026 Earnings, Measured Minute by Minute

Every earnings headline that crossed for Pfizer on 4 August 2026, with the price reaction measured from the instant each line printed.

Published in ET: Feed time in ET: Earnings PFE +0.64% in 15 min after the headline
  • Measured from the print at 10:45 UTC on 4 August 2026: $25.09 to $25.25 in fifteen minutes, +0.64%.
  • Every headline row is measured from its own instant, so the lines can be compared directly.
  • One-minute versus fifteen-minute readings show how fast the report was actually priced.

Reaction by asset (real prices)

Asset2m beforeAt release+1m+15m+1m %+15m %
PFE
Volume 27.8× normal in 15 min
25.09 25.09 24.98 25.25 -0.44% +0.64%

Pfizer reported, and the stock barely moved: +0.64% in the first fifteen minutes from 10:45 UTC. A flat print is information too — it says the result was already in the price.

This page is the measured anatomy of that print on 4 August 2026: every earnings-related headline that crossed for Pfizer, in order, each with the price reaction measured from its own instant.

The print, row by row

CrossedHeadline as recorded15-min move from that instantVolume vs normal
10:45 UTCPfizer Inc. (PFE) Q2 2026 (USD): Adj. EPS 0.77 (exp. 0.68), Revenue 15bln (exp. 14.40bln). FY adj. EPS view 2.80-3.00 (exp. 2.94), revenue 60.5-62.5bl+0.64%27.78x
10:45 UTCPfizer Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.95 Est; Raises FY2026 Sales Guidance from $59.500B-$62.500B to $60.500B-$62.500B vs $61.79+0.64%27.78x
11:03 UTCReported: $PFE Pfizer Q2 Earnings Adj. EPS $0.77, est. $0.68 | Rev. $15.03B, est. $14.41B | Eliquis rev. $2.43B, est. $2.09B-0.59%16.53x

Which line actually moved it

Each row above is measured from its own instant — the price immediately before that specific headline crossed — so the rows can be compared directly. The largest single reaction, +0.64%, belongs to the 10:45 UTC line. By the time the 11:03 UTC line arrived, the measured response was -0.59% — the marginal information in each successive headline decays fast, and the decay is measurable.

Did the first read hold?

It did. By the close of that session, Pfizer stood at +1.52% against the prior close — the same direction the first fifteen minutes priced. The instant read and the considered read agreed.

A reaction this small after a scheduled report is its own finding: the result matched what the price already implied. For anyone tracking this name into next quarter, the useful comparison is whether the market stays this settled.

How these numbers were measured

We record the price of the instrument immediately before each headline crosses our news feed, then again one minute and fifteen minutes later, together with traded volume against that instrument's own normal. Every figure on this page comes from those recordings — the timestamps are the actual instants the lines crossed. Nothing here is an estimate, a close-to-close change, or a model's guess. The method, the gates every page must pass, and how we correct errors are documented in our editorial standards.

How did Pfizer stock react to its Q2 2026 earnings?

Measured from the instant the first headline crossed on 4 August 2026 at 10:45 UTC, Pfizer moved from $25.09 to $25.25 over the following fifteen minutes — +0.64%. The measurement starts at the print itself, not at the open, so it isolates the report's own effect.

How fast was the report priced in?

One minute after the print the measured move was -0.44%; at fifteen minutes it was +0.64%. The gap between those two figures is the pricing-in window — how long the market took to finish reading.

Which headline moved Pfizer the most?

The 10:45 UTC line carried the largest measured reaction of the sequence at +0.64%. Later lines measured progressively less — repeat information decays within minutes.

Sources

  • Pfizer (PFE) earnings Q2 2026 - CNBC
    Pfizer reported Q2 2026 results on 4 August 2026: revenue $15.0bn up 2.6% beating expectations, adjusted EPS $0.77, a $4.3bn noncash impairment behind a $248mn net loss, and the full-year revenue guidance midpoint raised to $60.5-62.5bn.
  • Pfizer posts Q2 2026 earnings beat - Quartz
    Pfizer reported Q2 2026 results on 4 August 2026: revenue $15.0bn up 2.6% beating expectations, adjusted EPS $0.77, a $4.3bn noncash impairment behind a $248mn net loss, and the full-year revenue guidance midpoint raised to $60.5-62.5bn.

Never miss the next market-moving story

Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.

Create free accountGo real time Watch live headlines -- free
See live news
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Core market coverageEquities, macro, currencies and commodities Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Go real time View the live feed Subscription renews automatically. Cancel before renewal. Information only—no trade calls.